Onkologie. 2010:4(2):79-83

Actual trends in the radiotherapy of prostate cancer

Jiří Kubeš
Ústav radiační onkologie FN Bulovka a 1. LF UK, Praha

The paper describes actual trends in the radiotherapy of prostate cancer, with emphasis of radiobiological characteristics, the dose and

the fractionation, techniques of radiotherapy including IMRT, IGRT, stereotactic radiotherapy and brachytherapy. The combination of

the radiotherapy and the hormonal treatment is also discussed.

Keywords: radiotherapy, prostate cancer

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubeš J. Actual trends in the radiotherapy of prostate cancer. Onkologie. 2010;4(2):79-83.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fowler J, Chappell R, Ritter M. Is a/b for prostate tumors really low? Int. J. Radiation Oncology Biol. Phys. 2001; 50(4): 1021-1031. Go to original source... Go to PubMed...
    2. Fowler J, Ritter M, Chappell R. What hypofractionated protocols should be tested for prostate cancer? Int. J. Radiation Oncology Biol. Phys., 2003; 56(4): 1093-1104. Go to original source... Go to PubMed...
    3. Arcangeli G, Saracino B, Gomellini S, et al. A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients with High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2010 Jan 2 [Epub ahead of print]. Go to original source... Go to PubMed...
    4. Norkus D, Miller A, Kurtinaitis J, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlenther Onkol. 2009; 185(11): 715-721. Go to original source... Go to PubMed...
    5. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007; 67(4): 1099-1105. Go to original source... Go to PubMed...
    6. Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J. Weerasinghe Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006; 66(4): 1072-1083. Go to original source... Go to PubMed...
    7. Zietman A, Bae K, Slater J, et al. Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09, JCO Mar 2010: 1106-1111. Go to original source... Go to PubMed...
    8. Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with 18F-fluoride: applying new technology to an old tracer J Nucl Med. 2008; 49(1): 68-78. Go to original source... Go to PubMed...
    9. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53(5): 1097-1105. Go to original source... Go to PubMed...
    10. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294(10): 1233-1239. Go to original source... Go to PubMed...
    11. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24(13): 1990-1996. Go to original source... Go to PubMed...
    12. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8(6): 475-487. Go to original source... Go to PubMed...
    13. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008; 71(2): 330-337. Go to original source... Go to PubMed...
    14. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70(4): 1124-1129. Go to original source... Go to PubMed...
    15. Al-Mamgani A, Heemsbergen WD, Peeters ST, et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 73(3): 685-691. Go to original source... Go to PubMed...
    16. Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010; 10: 1. Go to original source... Go to PubMed...
    17. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67(1): 65-70. Go to original source... Go to PubMed...
    18. Bachand F, Martin AG, Beaulieu L, et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome. Int J Radiat Oncol Biol Phys. 2009; 73(3): 679-684. Go to original source... Go to PubMed...
    19. Martinez AA, Demanes J, Vargas C High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer. Am J Clin Oncol. 2009 Nov 30 [Epub ahead of print].
    20. Wilder RB, Barme GA, Gilbert RF, et al. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone. Brachytherapy. 2009 Oct 21. [Epub ahead of print]. Go to original source...
    21. Pouliot J, Aubin M, Langen KM, et al. (Non) - migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys. 2003; 56(3): 862-866. Go to original source... Go to PubMed...
    22. Moseley DJ, White EA, Wiltshire KL, et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line image-guided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys. 2007; 67(3): 942-953. Go to original source... Go to PubMed...
    23. Fung AY, Ayyangar KM, Djajaputra D, et al. Ultrasoundbased guidance of intensity-modulated radiation therapy Med Dosim. 2006; 31(1): 20-29. Go to original source... Go to PubMed...
    24. Rajendran RR, Plastaras JP, Mick R, et al. Daily isocenter correction with electromagnetic-based localization improves target coverage and rectal sparing during prostate radiotherapy Int J Radiat Oncol Biol Phys. 2010; 76(4): 1092-1099. Go to original source... Go to PubMed...
    25. M. Debois, N. Oyen and F. Maes, et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer, Int J Radiat Oncol Biol Phys 1999; 45: 857-865. Go to original source... Go to PubMed...
    26. John SS, Zietman AL, Shipley WU, et al. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. Int J Radiat Oncol Biol Phys. 2008; 71(1 Suppl): S43-47. Go to original source... Go to PubMed...
    27. D´Amico AV, CHen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-295. Go to original source... Go to PubMed...
    28. Denham JW, Steigler A, Lamb DS, et al. Short term androgen deprivation and radiotherapy fpr locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850. Go to original source... Go to PubMed...
    29. Alexander A, Crook J, Jones S, et al. Is biochemical response more important than duration of neoadjuvant hormone therapy efore radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. Int. J. Radiation Oncology Biol. Phys. 2010; 76(1): 23-30. Go to original source... Go to PubMed...
    30. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patiens with locally advanced prostate cancer/an EORTC study): a phase III randomized trial. Lancet 2002, 360: 103-106. Go to original source... Go to PubMed...
    31. Lawton CA, Winter K, Murray K, et al. Updated results of the phase IIII Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy fpr unfavorable prognosis carcinoma of the prostate. Int. J. Radiation Oncology Biol. Phys. 2001; 49: 937-946. Go to original source... Go to PubMed...
    32. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of longterm adjuvan androgen deprivation after neoadjuvant hormonal yctoreduction and radiotehrapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin. Oncol 2003; 21: 3972-3978. Go to original source... Go to PubMed...
    33. Heemsbergen WD, Peeters ST, Koper PC, et al. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys. 2006; 66(1): 3-10. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.